U.K.-based Advanced Medical Solutions (AMS) acquired French company Biomatlante, developer and manufacturer of orthobiologic products with application in joint reconstruction, spine, trauma and sports medicine procedures, for €8 million in cash (~USD $8.8 million), with a potential additional $0.3 million based on product approval milestones over two years. For 2018, Biomatlante reported revenue of $4.4 million.
The acquisition will supplement AMS’s present portfolio of surgical devices (sutures and topical adhesives) and wound care products. Biomatlante markets MBCP® synthetic bone graft in granule, putty and bespoke interbody cage insert formats, as well as the Osteotwin™ line of resorbable interference screws and instruments, primarily in Europe. AMS plans to globally expand Biomatlante’s product sales, and leverage Biomatlante’s presence in France for its own products.
Biomatlante’s founder, Dr. Guy Daculsi, will provide ongoing R&D and regulatory support through the end of 2021.
U.K.-based Advanced Medical Solutions (AMS) acquired French company Biomatlante, developer and manufacturer of orthobiologic products with application in joint reconstruction, spine, trauma and sports medicine procedures, for €8 million in cash (~USD $8.8 million), with a potential additional $0.3 million based on product approval milestones over...
U.K.-based Advanced Medical Solutions (AMS) acquired French company Biomatlante, developer and manufacturer of orthobiologic products with application in joint reconstruction, spine, trauma and sports medicine procedures, for €8 million in cash (~USD $8.8 million), with a potential additional $0.3 million based on product approval milestones over two years. For 2018, Biomatlante reported revenue of $4.4 million.
The acquisition will supplement AMS’s present portfolio of surgical devices (sutures and topical adhesives) and wound care products. Biomatlante markets MBCP® synthetic bone graft in granule, putty and bespoke interbody cage insert formats, as well as the Osteotwin™ line of resorbable interference screws and instruments, primarily in Europe. AMS plans to globally expand Biomatlante’s product sales, and leverage Biomatlante’s presence in France for its own products.
Biomatlante’s founder, Dr. Guy Daculsi, will provide ongoing R&D and regulatory support through the end of 2021.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
